Sequana Medical FIRST LOOK : First Ph 1/2 DSR 2.0 Cohort Maintains Encouraging Trends
Sequana reported positive data from the non-randomised cohort of the phase 1/2a (MOJAVE) study with DSR 2.0 for the treatment of congestive heart failure showing encouraging trends on diuretic response as well as kidney function with no safety concerns. The data is in line with an earlier interim readout (n=2), and it is worth noting that the results came in above what was previously observed in the RED DESERT and SAHARA trials. We believe Sequana is on the right path to pass the DSMB review in 1Q24 and progress toward the randomised portion of the MOJAVE trial aiming to confirm the benefits observed in the RED DESERT and SAHARA studies. With Sequana on track towards its milestones, our case remains unchanged and we reiterate our BUY rating and 7 € TP.Sequana Medical NV. Sequana Medical NV is a Belgium-based company, which manufactures medical devices. The Company focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.